World Down Syndrome Day-Be with us, not for us

What is Down Syndrome?

Down syndrome (DS) is a commonchromosomal abnormalities Birth defectsdisease. Humans have total.23 pairs of chromosomes, each pair of two, a total of 46. Down's syndrome is when chromosome 21 changes from two to three..

According to the China Birth Defects Prevention Report (2012) "shows that there are currently 1 million patients with Down's syndrome in my country, with 2.3-25000 new cases every year, and an average of one" baby Tang "is born every 20 minutes. The main manifestations of patients are mental retardation, developmental retardation, multiple deformities, special faces, and unable to take care of themselves completely..

Down'sSyndromeis an episodic disease,namelyevery healthy couple hasmaybirth"Tang Baobao".

How to Prevent Down Syndrome

and effective prenatal screening is the most effective measure to prevent and treat Down syndrome. Currently, prenatal screening for Down's syndrome includes Down's screening and noninvasiveDNA Prenatal ScreeningTechnology.

Down's screening, that is, the fasting venous blood of pregnant women, the determination of biochemical markers in serum, combined with the age of pregnant women, gestational weeks, weight, etc., to calculate the occurrence of Down's syndrome in the fetusvalue. The detection rate of this technology isabout 70%, there is a false positive rate of about 5%.

non-invasiveDNA prenatal screening technology,is pumpingvenous blood of pregnant women, usinghigh throughputsequencingDNA fragments (including cell-free fetal DNA) for sequencing,thenbioinformatics analysis to detect three chromosomal disorders in the fetus(with Down syndrome). The technology has a high detection rate, upmore than 95%, the false positive rate of low characteristics.

Serena based on amplicon sequencing technology

non-invasiveDNA Prenatal Screening

Serena (China) Medical Technology Co., Ltd. is a high-tech enterprise with advanced diagnostic technology. It set up its headquarters in Chengdu in 2013 and set up branches and offices in Shanghai, Hengqin, Zhuhai, Beijing and San Diego, California. The company has a complete R & D, product transformation, production and service base of more than 5000 square meters, and a multidisciplinary technical and marketing team of nearly 100 people. Through years of technology research and development in the United States and China, it has successfully launched miniaturized Sparrow flow cytometry suitable for medical institutions at all levels in China, and supporting detection kits for many major diseases such as reproduction and immunity. Serena also has a new generation of targeted non-invasive prenatal genetic testing (NIPT) technology. The product has the obvious advantages of more accurate detection, more detection content and lower cost, which can be popularized in earlier gestational weeks and wider population.

Serena (China) will continue to carry out technological innovation to provide more complete and more HP diagnostic products.